ClinicalTrials.gg
RecruitingNCT07909486VNSUpdated Nov 2, 2026

Identification of Biomarkers for Vagus Nerve Stimulation in Patients With Refractory Epilepsy

An interventional study of Vagus nerve stimulation in Refractory Epilepsy, sponsored by Cliniques universitaires Saint-Luc- Université Catholique de Louvain. Recruiting at 1 site in Belgium. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Cliniques universitaires Saint-Luc- Université Catholique de Louvain · Not applicable, Interventional, and Other

From the registry’s dates

  • Registered 1 year 9 months after the study started (first participant enrolled Feb 2022, registered Dec 2023).
  • Started Feb 2022; still recruiting 4 years 8 months later.
Updated Nov 2, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 79 Years
Sex
All
01

Study summary

A VNS longitudinal study focused on pre and post-VNS implantation in order to predict the VNS response and to understand better mechanisms of VNS using some connectivity and network measures.

02

Conditions studied

  • Refractory Epilepsy
03

In context

Drug Resistant Epilepsy

275 studies on the registry are indexed under Drug Resistant Epilepsy; 104 are open to participants now.

This study's planned enrollment of 20 is below the median of 30 across 217 interventional studies indexed under Drug Resistant Epilepsy.

Browse Drug Resistant Epilepsy studies →

Lead sponsor

Cliniques universitaires Saint-Luc- Université Catholique de Louvain is the lead sponsor of 349 studies on the registry; 63 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged >18 years
  • Intelectual Quotient >55 on Wechsler scale (normal or mild cognitive impairment)
  • Patients have refractory epilepsy and are planned for VNS implantation

Exclusion criteria

Exclusion Criteria:

  • Concomitant laryngeal pathology (e.g. recurrent nerve lesions, vocal fold paralysis).
  • Dementia/ Neurodegenerative diseases
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    VNS Implanted Group

    We will compare responders with non-responders to VNS, but both are part of the implanted arm.

    Device: Vagus nerve stimulation

Interventions

  • DeviceVagus nerve stimulation

    No intervention was performed for the study, since VNS is already part of the treatment of these patients. However, VNS parameters are changed for the sake of the study and reestablished at the end.

06

What researchers measure

Primary outcomes

  1. Pupillometry

    Using an eye-tracking camera, we will record pupil dilation responses (PDR) induced by both VNS and an oddball paradigm. The PDR signals (measured in arbitrary units and converted to mm) will be aligned with the corresponding stimulus in order to extract the trials. From these, classical PDR metrics such as peak amplitude or latency can be derived.

    Time frame: Before Implantation, 3 Months, and 6 Months Post Implantation

  2. P300

    The P300 component of the evoked potential can be extracted from electroencephalography (EEG) signals as a wave peaking around 300 ms after a given stimulus. An auditory oddball paradigm will be employed as the stimulus. Then, we derive classical metrics from the P300, such as amplitude and latency.

    Time frame: Before Implantation, 3 Months, and 6 Months Post Implantation

  3. LMEP

    We aim to record a reproducible and quantifiable VNS-induced laryngeal motor-evoked potential (LMEP) from the electromyography (EMG) signal at the larynx level. After filtering the signal, the relevant component that is expected to be observed consists of the artefacts generated by the ON periods of the VNS - each VNS pulse will contain a laryngeal response, which appears right after the VNS pulse. With this laryngeal response detected, the LMEP will be characterised by quantitative features including peak amplitude (μV) and latency (ms).

    Time frame: Before Implantation, 3 Months, and 6 Months Post Implantation

Secondary outcomes

  1. Response assessment

    At 6 months, we will evaluate the seizure frequency reduction compared to 3 months before implantation.

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07909486
Responsible party
Sponsor
First posted
Nov 2, 2026
Start date
Feb 28, 2022
Primary completion
Sep 1, 2025
Completion
Dec 2028 (estimated)
Last update
Nov 2, 2026

Study contacts

Riëm EL TAHRY, Pr.
Contact
riem.eltahry@uclouvain.be
+322 764 28 55

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion